研究課題/領域番号 |
19K16699
|
研究機関 | 東京医科大学 |
研究代表者 |
尹 晶煥 東京医科大学, 医学部, 兼任助教 (30748885)
|
研究期間 (年度) |
2019-04-01 – 2022-03-31
|
キーワード | Lung cancer / Anti-tumor immunity / Dendritic cell / T cell / TGF-beta / SMADs / STATs |
研究実績の概要 |
<Plan 1: Roles of SMADs in DCs and T cells in immune homeostasis> I found that T cell and DC-specific Smad2 and Smad4 deficient mice showed normal immune phenotypes, whereas Smad3 KO mice showed deficiency in a certain DC subset in the steady-state condition. <Plan 2: Roles of SMADs in DCs and T cells in lung cancer> I have applied the mouse Lewis lung carcinoma metastasis model: Ex3LL-luc to T cell and DC-specific Smad2 and Smad4 deficient mice. Clinical courses have been evaluated by IVIS imaging system. <Plan 3: Effects of SMAD deficiency on STAT signaling in DCs and T cells in lung cancer> I have found that SMAD2 deficient conventional DCs upregulated the differentiation and anti-lung cancer functions of cytotoxic T cells in Ex3LL-luc-bearing mice. <Plan 4: Mechanisms how SMAD-STAT signaling networks regulate DCs and T cells in anti-lung cancer immunity> I have discovered the novel regulatory interaction between STAT and SMADs in T cell and DC differentiation in lung cancer microenvironment. I have generated the adeno-associated virus vectors expressing the various constitutively active or inactive mutants of SMADs and STAT3 to elucidate the molecular mechanisms of SMAD-STAT signaling networks.
|
現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
As stated in the summary, I have made progress in accordance with the proposed plans.
|
今後の研究の推進方策 |
I will finish revising the submitted manuscript on the role of SMAD3 in DC development <Plan 1>. I will finish <Plan 2> and <Plan 3> to submit the second manuscript of this project. To complete <Plan 4>, I will perform ChIP sequencing and RNA-sequencing of effector T cells and DCs from Ex3LL-luc-bearing mice (Macrogen, Korea).
|
次年度使用額が生じた理由 |
Due to the pandemic, I could not spend all the FY2020 budget. I will make a payment with the balance mainly for sequencing.
|